| Dr Simon R Russin, DO | |
|
301 E City Ave, Suite G2, Bala Cynwyd, PA 19004-1708 | |
| (610) 617-4177 | |
| (610) 617-4170 |
| Full Name | Dr Simon R Russin |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 30 Years |
| Location | 301 E City Ave, Bala Cynwyd, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407852049 | NPI | - | NPPES |
| 001697374 | Medicaid | PA | |
| 10935353 | Other | PA | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | OS009908L (Pennsylvania) | Primary |
| Entity Name | Russin Eye Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720255508 PECOS PAC ID: 5092874883 Enrollment ID: O20081107000720 |
News Archive
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.
A recent study investigates the paradoxical effects of dosage and dosing interval on COVID-19 vaccine efficacy.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment.
George Washington University (GW) researchers report dramatic increases in prescriptions of opioid analgesics, such as Percocet, Vicodin, oxycodone and Dilaudid, during U.S. emergency department visits from 2001 to 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Simon R Russin, DO 301 E City Ave, Suite G2, Bala Cynwyd, PA 19004-1708 Ph: (610) 617-4177 | Dr Simon R Russin, DO 301 E City Ave, Suite G2, Bala Cynwyd, PA 19004-1708 Ph: (610) 617-4177 |
News Archive
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.
A recent study investigates the paradoxical effects of dosage and dosing interval on COVID-19 vaccine efficacy.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment.
George Washington University (GW) researchers report dramatic increases in prescriptions of opioid analgesics, such as Percocet, Vicodin, oxycodone and Dilaudid, during U.S. emergency department visits from 2001 to 2010.
› Verified 4 days ago
Dr. David H Fischer, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 100 Presidential Blvd, Suite 100, Bala Cynwyd, PA 19004 Phone: 610-667-1312 | |
Dr. Brenton David Finklea, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 Presidential Blvd Ste 200, Bala Cynwyd, PA 19004 Phone: 484-434-2700 Fax: 610-660-0419 | |
Ralph J Di Giovanni Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 501 Belmont Ave, Bala Cynwyd, PA 19004 Phone: 610-667-4066 Fax: 610-667-7955 | |
Marvin H Greenbaum, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 501 Belmont Ave, Bala Cynwyd, PA 19004 Phone: 610-667-4066 Fax: 610-667-7955 | |
Dr. Fred Kremer, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 621 Conshohocken State Rd, Bala Cynwyd, PA 19004 Phone: 610-453-1701 | |
Dr. Leonard B Nelson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 Presidential Blvd Ste 200, Bala Cynwyd, PA 19004 Phone: 484-434-2700 Fax: 610-660-0419 | |
Dr. Alfred C Lucier, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 100 Presidential Blvd, Suite 200, Bala Cynwyd, PA 19004 Phone: 610-660-0446 Fax: 610-660-0419 |